Any exploration of IL-17-targeted strategies for PD should balance potential benefits for inflammation and bone resorption with risks related to mucosal defense and candidiasis, given safety observations from the dermatologic use of IL-17 blockade [58], and the documented dual roles of IL-17 in experimental models and human observational studies [7,43,56]. The gene discussed is IL17A; the disease is Candidiasis, Invasive.